CPT-11, Carbopplatin, Dexamethasone commbination chemotherapy for refractory aggressive lymphoma

CPT-11, Carbopplatin, Dexamethasone commbination chemotherapy for refractory aggressive lymphoma - CPT, CBDCA, Dex for aggresive lymphoma

Status

Recruiting

Phases

Phase 2

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000004501

Enrollment

Registered

2010-11-03

Start date

2010-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

refactory aggressive lymphoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. refractory for first line chemotherapy 2. age between 18 and 70 3. PS 0-2 4. expected to be alive for 3 months 5. normal of hematopoiesis and liver and renal function tests

Exclusion criteria

Exclusion criteria: 1. anaphylasis foo\r carboplatin 2. diarrhea 3. ileus 4. peptic ulcer 5. interstitial pneumonitis

Design outcomes

Primary

Measure	Time frame
response rate	—

Secondary

Measure	Time frame
adverse event	—

Countries

Japan

Contacts

Public ContactNorifumi Tsukamoto

Gunma University graduate school Medicine and Clinicla Science

027-220-8166

Outcome results